For the past 2 years Inospin has been working with Boehringer Ingelheim and the opnMe team regarding multiple industry-academia collaboration programs. One of their first collaboration resulted in a publication in Nature last fall.
On March 25th 2021, Boehringer Ingelheim organised a live online seminar webinar about Chemically induced degradation of the Oncogenic Transcription factor BCL6.
Watch the recording of the online seminar on opnMe.com
About BCL6 Degrader BI-3802:
BCL6 degrader BI-3802 is a single digit nanomolar BCL6::Co-repressor inhibitor which induces efficacious BCL6 protein degradation and represents ideal in vitro probe compound for testing hypotheses around BCL6 biology. The molecule is made available on opnMe.com free of charge to foster independent innovation of scientific groups.
1Small-molecule-induced polymerization triggers degradation of BCL6 Słabicki M., Yoon H., Koeppel J., Nitsch L., Roy Burman S. S., Di Genua C., Donovan K. A., Sperling A. S., Hunkeler M., Tsai J. M., Sharma R., Guirguis A., Zou C., Chudasama P., Gasser J. A., Miller P. G., Scholl C., Fröhling S., Nowak R. P., Fischer E. S., Ebert B. L. Nature 2020, 588, 164–168.
About opnMe Program from Boehringer Ingelheim:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, molecules are provided to the scientific community to help unlock and fulfil their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of the third pillar, “opn2EXPERTS” program, Boehringer Ingelheim also enlists scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.
The mystery of BI-3802’s BCL6 induced protein degradation is finally solved! The unique mode of action was recently published in Nature1 and received a lot of publicity. Panel of speakers consisted of Mikołaj Słabicki, Hojong Yoon, and Jonas Koeppel from Dana-Farber Cancer Institute and Manfred Koegl and Steffen Steurer from Boehringer Ingelheim, who presented and discussed the details of BI-3802’s mechanism.
The speakers
Watch the recording of online seminar
About Inospin:
Inospin is the #1 partnering network for Scientific Innovations with more than 500 innovation-driven leading companies with active external R&D programs, which are available on dedicated partnering platforms where academics and SMEs can submit their proposals for collaboration.